Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.

Nature genetics - 1 Jun 1999

Drazen J M, Yandava C N, Dubé L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman E S, Katz D A, Drajesk J

Abstract excerpt

Clinically similar asthma patients may develop airway obstruction by different mechanisms. Asthma treatments that specifically interfere with the 5-lipoxygenase (ALOX5) pathway provide a method to identify those patients in whom the products of the ALOX5 pathway (that is, the leukotrienes) contribute to the expression of the asthma phenotype. Failure of an asthma patient to respond to treatment with ALOX5-pathway...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Anti-Asthmatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arachidonate 5-Lipoxygenase

Share to Asthma

Share to Gene Frequency

Share to Hydroxyurea

Share to Promoter Regions, Genetic

Share to Treatment Outcome

Source

Identifiers

PMID: 10369259
DOI: 10.1038/9680

Genes

ALOX5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.PMID 10369259Read ↗

ALOX5 promoter genotype, asthma severity and LTC production by eosinophils.Semantic proximity Read ↗

ALOX5 polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma.Semantic proximity Read ↗

Pharmacogenetics of the 5-lipoxygenase pathway in asthma.Semantic proximity Read ↗

Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population.Semantic proximity Read ↗

Functional variants of the human 5-lipoxygenase gene and their genetic diagnosis.Semantic proximity Read ↗

5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists.Semantic proximity Read ↗

Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.Semantic proximity Read ↗

ALOX5 promoter genotype and response to montelukast in moderate persistent asthma.Semantic proximity Read ↗

LTC4 production by eosinophils in asthmatic subjects with alternative forms of ALOX-5 core promoter.Semantic proximity Read ↗

Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukastSemantic proximity Read ↗

Mutations in the human 5-lipoxygenase gene.Semantic proximity Read ↗

Genetic variations in the 5-lipoxygenase core promoter. Description and functional implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.